Teva agrees to settle patent litigation regarding generic version of AstraZeneca's Entocort EC capsules

NewsGuard 100/100 Score
May 18 2010

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into an agreement with AstraZeneca to settle patent litigation regarding Teva's U.S. generic version of AstraZeneca's Entocort EC (budesonide) capsules.

Under the terms of the agreement, AstraZeneca has granted Teva an exclusive license to enter the U.S. market with its generic budesonide capsules on February 15, 2012, subject to regulatory approval, or earlier in certain circumstances. Other terms of the settlement are confidential.

Entocort EC (budesonide) capsules had annual sales of approximately $265 million in the United States, based on IMS sales data.

Source:

Teva Pharmaceutical Industries Ltd.

Posted in: Medical Patent News | Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites
Lancet Commission predicts sharp increase in global prostate cancer cases
Supply chain assessment and management, optimizing pharmaceutical supply chains
Common HIV drugs linked to reduced Alzheimer's disease risk
Recycled food waste may be contaminated with pharmaceutical residues, research reveals
SCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass Spectrometry
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients